Расширенный поиск

Результаты исследования TORCH: новая эпоха в терапии ХОБЛ

Полный текст:

Об авторах

З. Р. Айсанов
ФГУ НИИ пульмонологии Росздрава
г. Москва

Е. Н. Калманова
ФГУ НИИ пульмонологии Росздрава
г. Москва

Список литературы

1. Global initiative for chronic obstructive lung disease home page. (Accessed February 1, 2007, at

2. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970–2002. J. A. M. A. 2005; 294: 1255–1259.

3. Anthonisen N.R., Connett J.E., Murray R.P., for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675–679.

4. Crockett A.J., Cranston J.M., Moss J.R., Alpers J.H. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Intern. Med. J. 2001; 31: 448–454.

5. Fishman A., Martinez F., Naunheim K. et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059–2073.

6. Sin D., Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 580–584.

7. Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after use of salmeterol and/or fluticasone propionate in general practice. Eur. Respir. J. 2002; 20: 819–825.

8. Waterhouse J.C., Fishwick D., Anderson J.A. et al. What caused death in the ISOLDE study? Eur. Respir. J. 1999; 14 (suppl. 30): 387s.

9. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–57.

10. Vestbo J., TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. 2004; 24: 206–210.

11. Burge P., Calverley P., Jones P. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit. Med. J. 2000; 320: 1297–1303.

12. Calverley P.M.A., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.

13. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.

14. Calverley P.M.A., Anderson J.A., Celli B. et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789 & Online Supplements.

15. Altman D.G. Practical statistics for medical research. London: Chapman and Hall; 1991.

16. Pocock S.J. Clinical trials. London John: Wiley and Sons; 1984; 205.

17. Shakespeare T.P., Gebski V.J., Veness M.J., Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves and risk-benefit contours. Lancet 2001; 357: 1349–1353.

18. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.

19. Flather M.D., Yusuf S., Kober L. et al. Long term ACEinhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575–1581.

20. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. 2004; 164: 1427–1436.



Для цитирования:

Айсанов З.Р., Калманова Е.Н. Результаты исследования TORCH: новая эпоха в терапии ХОБЛ. Пульмонология. 2007;(5):88-93.

For citation:

Aisanov Z.R., Kalmanova E.N. Results of the TORCH trial: a new era in the therapy of COPD. PULMONOLOGIYA. 2007;(5):88-93. (In Russ.)

Просмотров: 164

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)